January 12, 2022 at 7:30 AM EST JP Morgan 40th Annual Virtual Healthcare Conference Click here for Webcast Supporting Materials JP Morgan 40th Annual Virtual Healthcare Conference Presentation 2.5 MB Pagination Current page 1 Page 2 Next page next › Last page last » SHARE PRICE > View All Stock Detailed Share Information Latest News Molecular Partners Finalizes License Agreement with Novartis for Ensovibep for COVID-19 Molecular Partners Reports Disclosure of Major Shareholder as per Swiss Stock Exchange Regulations Molecular Partners and Novartis Report Positive Topline Data from Phase 2 Study for Ensovibep (MP0420), a DARPin Antiviral Therapeutic for COVID-19 > View All News All News Upcoming Events April 13, 2022 Annual General Meeting March 15, 2022 Expected Publication of FY 2021 Annual report and audited 2021 results > View All Events All Events Latest Presentation January 12, 2022 JP Morgan 40th Annual Virtual Healthcare Conference Presentation January 10, 2022 Ensovibep Clinical Results Call Presentation January 10, 2022 HC Wainwright Healthcare Conference Presentation > View All Presentations All Presentations Latest Financial Documents October 28, 2021 Q3 2021 Financial Statement August 26, 2021 Half Year Report 2021 February 26, 2021 Annual Report FY2020 > View All Reports All Annual Report Seth Lewis, SVP Investor Relations, Communications and Strategy Contact Seth STAY INFORMED Subscribe to email alerts of your choosing SUBSCRIBE Institutional investors: REQUEST 1-1 / CALL powered by schedulR
January 12, 2022 at 7:30 AM EST JP Morgan 40th Annual Virtual Healthcare Conference Click here for Webcast Supporting Materials JP Morgan 40th Annual Virtual Healthcare Conference Presentation 2.5 MB
Molecular Partners and Novartis Report Positive Topline Data from Phase 2 Study for Ensovibep (MP0420), a DARPin Antiviral Therapeutic for COVID-19
